Align Technology, Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a ALGN research report →
Range $162 – $215
Price Chart
About the company
Align Technology, Inc. is a medical technology enterprise that develops, produces, and markets its leading products: Invisalign transparent dental aligners and iTero digital intraoral scanners, along with related services. These offerings serve a wide range of dental professionals, including orthodontists, general dentists, and those specializing in restorative and cosmetic dentistry.
- CEO
- Joseph Hogan
- IPO
- 2001
- Employees
- 20,290
- HQ
- Tempe, AZ, US
AI snapshot
Six angles, distilled from the data.
The stock is in a recovery phase after a long pullback from its 52-week high of 200.44, but it remains below the 200-day moving average around 168.7. The 50-day average near 152.4 sits below the current regime, signaling a rebound that still needs confirmation before the trend turns fully constructive.
Street sentiment is constructive but cautious: consensus sits at Buy with a 190 target, above the last close. Recent calls have leaned lower on price targets, including cuts from Morgan Stanley, Piper Sandler, Leerink, and Stifel, while the broader rating mix still skews positive at 22 Buy, 9 Hold, and 2 Sell.
The earnings profile is mixed but workable: ALGN has beaten EPS in 5 of the last 8 quarters, including a 2.2% beat last quarter. Next-year EPS estimates point sharply higher to 12.29 from 6.86 TTM, so shareholders should watch whether margin discipline and demand can support that step-up.
No discretionary insider buying or selling stands out; the recent activity is dominated by awards, exempt vesting, and administrative share movements. That pattern points to routine compensation-related flows rather than a directional signal from management or directors.
Profitability remains solid, with a 71.5% gross margin, 19.64% operating margin, and 11.83% net margin. Revenue growth is modest at 1.9% year over year, but earnings growth is much stronger, and the balance sheet is net cash positive by about $980.5 million.
ALGN still screens as a premium medical-device name, supported by high gross margins and a strong cash position. Versus peers, the setup favors a quality franchise with a valuation that remains tied to execution rather than cheapness; the market is paying for margin durability and growth reacceleration.
Similar companies
Peers in the same neighborhood.
- Market Cap
- $10.94B
- P/E
- 23.21
- Fwd P/E
- 13.95
- PEG
- 0.70
- P/S
- 2.71
- P/B
- 2.63
- EV/EBITDA
- 13.77
- Div Yield
- 0.00%
- Gross Margin
- 67.58%
- Op Margin
- 15.02%
- Net Margin
- 11.83%
- ROE
- 11.76%
- ROIC
- 10.28%
Latest fiscal year · YoY change
- Revenue
- $4.03B+0.9%
- Gross Profit
- $2.76B-1.5%
- Op Income
- $616.22M
- Net Income
- $410.35M-2.6%
- EPS
- $5.66+0.5%
- OCF Growth
- -19.6%
- FCF Growth
- -21.2%
- 52W High
- $200.44
- 52W Low
- $132.64
- 50D MA
- $152.42
- 200D MA
- $168.72
- Beta
- 1.74
- RSI (14)
- 45
- Avg Volume
- 1.01M
Earnings call summaries
Pick a quarter — each call distilled into takeaways, results, and a bull vs bear read.
Align delivered modest Q3 revenue growth and stronger profitability, while laying out a more cautious Q4 revenue outlook and a 2027 plan centered on continued volume growth, margin expansion and new digital-product adjacencies.· October 28, 2026
- Q3 revenue was $1.015 billion, up 1.9% year over year, with Clear Aligner shipments rising 6.6% to 691,000 and doctor submitters reaching a record 91,000.
- Non-GAAP gross margin was 70.4% and non-GAAP operating margin was 24.4%, with management saying expense discipline and productivity more than offset a modest gross margin shortfall.
- Systems and Services revenue fell 7.6% to $175.5 million as Align shifted toward lower-priced scanner configurations and more flexible acquisition models.
- Management said the macro environment remains challenging, with softer discretionary spending and weaker consumer conversion especially in North America GP retail.
- The company guided to Q4 revenue of $1 billion to $1.020 billion and full-year 2026 revenue of $4.11 billion to $4.13 billion, while reiterating about 5% to 6% Clear Aligner growth for 2026 and outlining at least another 100 basis points of non-GAAP operating margin improvement in 2027.
Third-quarter revenue was $1,014.8 million, up 1.9% year over year and 2.4% in constant currency. Clear Aligner revenue was $839.3 million, up 4.2% year over year, while Systems and Services revenue was $175.5 million, down 7.6%. Q3 gross margin was 68.7% on a GAAP basis and 70.4% on a non-GAAP basis, with non-GAAP gross margin flat year over year. Q3 operating margin was 16.7% GAAP and 24.4% non-GAAP; diluted EPS was $1.90 GAAP and $2.80 non-GAAP, with non-GAAP EPS up 7.3% year over year. Cash and cash equivalents were $1.145 billion at September 30, cash from operations was $183.2 million, capex was $45.1 million and free cash flow was about $138 million. For Q4 2026, management expects revenue of $1 billion to $1.020 billion, Clear Aligner volume up low single digits year over year, Clear Aligner ASP down about 1%, Systems and Services revenue of $170 million to $180 million, GAAP gross margin of about 71%, non-GAAP gross margin of about 72%, GAAP operating margin of about 20% and non-GAAP operating margin of about 26%. For full-year 2026, Align expects revenue of about $4.11 billion to $4.13 billion, Clear Aligner volume and revenue growth of about 5% to 6% year over year, Systems and Services revenue of $715 million to $725 million, GAAP operating margin of about 16.2%, non-GAAP operating margin of about 23.7%, capex of $125 million to $150 million and about $500 million of share repurchases.
Joe Hogan said the quarter showed Align can execute in a difficult market, citing record doctor submitters, record Q3 Clear Aligner shipments, improved utilization and strong international growth. He emphasized several growth levers: broader orthodontist utilization, more GP adoption, DSO growth, younger-patient products, affordability tools, and a more integrated digital platform that links scanning, diagnostics, treatment planning and restorative workflows. He also highlighted the CEO succession plan and reiterated confidence in the transition, saying he believes Jennifer Davis is the right leader to build on Align’s foundation.
John Morici walked through the numbers and the key drivers behind the quarter and outlook. He pointed to Q3 revenue of $1,014.8 million, non-GAAP gross margin of 70.4%, non-GAAP operating margin of 24.4%, EPS of $2.80 non-GAAP, and $1.145 billion of cash, plus $183.2 million of operating cash flow and $138 million of free cash flow. He said gross margin was pressured by lower Clear Aligner ASP, mix and freight, while Systems and Services revenue reflected a deliberate move to lower-priced scanners and more leasing/rental/certified-preowned models; he also said like-for-like scanner pricing stabilized. On capital allocation, he noted $103.3 million of buybacks in Q3, $200 million repurchased year to date and an expectation to repurchase about $500 million in 2026.
Analysts pressed on why Q4 case growth guidance was only low single digits after a strong Q3, and management said the guidance reflects a broad-based, cautious consumer backdrop across many markets rather than a single issue. Questions on China VBP were answered with the view that Align is exposed mainly on the private side, expects to participate, and sees the issue as neutral to positive overall because volume could offset pricing pressure. On scanners, management said the mix shift to leasing/rental and lower-priced configurations is not a demand problem but a customer-preference shift that has stabilized in Q3 and should support installed-base growth and, ultimately, more digital adoption.
The bull case from this call is that Align is still growing revenue and volumes despite a weak consumer environment, with record submitters, solid Clear Aligner growth and broad international strength. Management also sounded confident that 2027 can bring another year of revenue growth and at least another 100 basis points of non-GAAP operating margin improvement, without assuming a consumer recovery.
The biggest bear case is that discretionary demand remains weak, especially in North America GP retail, and management’s Q4 guidance implies continued caution on case starts and scanner revenue. The shift to lower-priced scanner models and lower Clear Aligner ASPs also pressures reported revenue, and even management framed 2026 as a transition year for Systems and Services and said the macro backdrop has not improved materially.
AI summary of the company's earnings call · Paraphrased · Not investment advice
- Free Float
- 94.2%
- Shares Outstanding
- 70.49M
- Float Shares
- 66.38M
of shares held by institutions
712 13F filers
Buy/sell ratio 0.00. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Congressional trading
Senate and House stock disclosures for ALGN, newest first.
| Member | Type | Traded | |
|---|---|---|---|
| Ro KhannaHouse · CA17 | Sell | Sep 11, 26 | Filing → |
| Ro KhannaHouse · CA17 | Sell | Sep 4, 26 | Filing → |
| Ro KhannaHouse · CA17 | Sell | Jan 29, 26 | Filing → |
| Lisa C. McClainHouse · MI09 | Sell | Sep 11, 25 | Filing → |
| Lisa C. McClainHouse · MI09 | Buy | Aug 4, 25 | Filing → |
| Robert P. BresnahanHouse · PA08 | Sell | Apr 8, 25 | Filing → |
| Robert P. BresnahanHouse · PA08 | Buy | Feb 25, 25 | Filing → |
| Gilbert CisnerosHouse · CA31 | Sell | Feb 26, 25 | Filing → |
| Ro KhannaHouse · CA17 | Buy | Sep 9, 24 | Filing → |
| Ro KhannaHouse · CA17 | Buy | Sep 9, 24 | Filing → |
| Josh GottheimerHouse · NJ05 | Sell | May 20, 24 | Filing → |
| Ro KhannaHouse · CA17 | Buy | Feb 13, 24 | Filing → |
| Ro KhannaHouse · CA17 | Buy | Jan 10, 24 | Filing → |
| Ro KhannaHouse · CA17 | Sell | Nov 3, 23 | Filing → |
Source: public STOCK Act disclosures. Filed weeks after the trade — a lagging signal, not a real-time one.
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Vanguard Group Inc | 8.18M | ▼ 121.83K |
| Fmr LLC | 5.53M | ▲ 1.47M |
| Blackrock, Inc. | 4.48M | ▲ 62.97K |
| Capital International Investors | 4.48M | ▲ 433.45K |
| Vanguard Capital Management LLC | 4.37M | ▼ 35.40K |
| Capital World Investors | 3.63M | ▲ 209.95K |
| Vanguard Portfolio Management LLC | 3.11M | ▼ 25.98K |
| Goldman Sachs Group Inc | 2.76M | ▼ 609.78K |
| State Street Corp | 2.58M | ▲ 23.46K |
| Geode Capital Management, LLC | 2.32M | ▲ 69.76K |
| Ninety One Uk Ltd | 2.13M | ▼ 76.17K |
| Ubs Group AG | 1.96M | ▼ 163.11K |
Held by 872 ETFs
Biggest fund positions in ALGN by dollar value.
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Nov 17, 26 | Clancy Paul J | other | 903 |
| Nov 17, 26 | Clancy Paul J | other | 0 |
| Nov 2, 26 | Davis Jennifer L. | other | 0 |
| Aug 27, 26 | Blackford Quentin S. | other | 1,376 |
| Aug 27, 26 | Blackford Quentin S. | other | 0 |
| May 20, 26 | Vitalone Britt J. | other | 1,836 |
| May 20, 26 | Vitalone Britt J. | other | 1,443 |
| May 20, 26 | Vitalone Britt J. | other | 1,443 |
| May 20, 26 | SIEGEL SUSAN E | other | 1,745 |
| May 20, 26 | SIEGEL SUSAN E | other | 1,836 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our ALGN coverage
Recent articles, reports, and earnings notes.

Align Technology (ALGN): Margin Recovery and Valuation Upside
Align Technology combines a strong balance sheet, improving margins, and a leading Invisalign franchise, but 2026 growth guidance remains modest. The stock looks attractive for moderate-risk investors if margin recovery and international demand continue to build.

SmileDirectClub, IPO: What to Know Before It Lists
SmileDirectClub, Inc. is expected to list on NASDAQ on 2026-11-18, but the price range has not been disclosed. The company is a direct-to-consumer oral care and medtech platform built around teledentistry and clear aligners. Watch for how investors weigh fast revenue growth against regulatory risk, litigation, and leverage.

Inside the vVARDIS Holding AG IPO: Growth, Risks, and Verdict
vVARDIS Holding AG Class A is expected to list on the NYSE on 2026-11-13 in a priced IPO at $21.00 to $24.00 per share. The Swiss oral-health company is coming public with rapid revenue growth, but it is still loss-making and heavily dependent on U.S. adoption of its core product.
Want a deeper read on ALGN?
Generate a full analyst-grade report — bull/bear case, price targets, valuation depth, and a complete financial breakdown.
Align Technology Sees iTero Revenue Rebound in 2027 After Pricing Cuts Outlook
marketbeat.com · Nov 19
Paul J. Clancy and Ian Bell to Join Align Technology Board of Directors
businesswire.com · Nov 18
Align Technology, Inc. (ALGN) Presents at Jefferies Global Healthcare Conference 2026 Transcript
seekingalpha.com · Nov 17
Should You Continue to Hold ALGN Stock in Your Portfolio?
zacks.com · Nov 17
Allworth Financial LP Buys 112,182 Shares of Align Technology, Inc. $ALGN
defenseworld.net · Nov 14
Align Technology, Inc. $ALGN Position Increased by AlphaCore Capital LLC
defenseworld.net · Nov 11
Align Technology to Speak at Upcoming Financial Conference
businesswire.com · Nov 10
Align Technology Recognized in Extel's 2026 All-America Executive Team Rankings
businesswire.com · Nov 6
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.
AI analysis · Last refreshed November 21, 2026 · Live quote · Not investment advice